NANOWOUND
Financiado
Antibacterial wound dressing based on advanced nanotechnology to improve the eff...
Antibacterial wound dressing based on advanced nanotechnology to improve the efficiency of wound care
Infected wounds are a major cause of limb amputations among patients with chronic diseases like diabetes. 10mln amputations occur annually causing €100bln additional healthcare costs. During COVID-19 pandemic the number of amputat...
Infected wounds are a major cause of limb amputations among patients with chronic diseases like diabetes. 10mln amputations occur annually causing €100bln additional healthcare costs. During COVID-19 pandemic the number of amputations rose 10 fold due to low efficacy of current solutions.
Nanordica develops an advanced Antibacterial Wound Dressing (AWD) to prevent and treat wound infections. We have demonstrated that our AWD removes bacterial infection 8x better than current best. Our value propositions are high efficacy and low cost.
Global antibacterial wound dressing market is projected to reach €4.2bln in 2026 at CAGR 5.7%. Our business model is B2B using distributors to reach our customers, i.e. hospitals. We have a priority for intellectual property and initiated a pilot clinical trial at the largest Estonian hospital.
Our mission is to bring AWD to the market to improve the outcome of wound infections, lower healthcare costs and help hundreds of millions of patients.
ver más
Duración del proyecto: 27 meses
Fecha Inicio: 2022-12-14
Fecha Fin: 2025-03-31
Fecha Fin: 2025-03-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-14
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
NANORDICA MEDICAL OU
No se ha especificado una descripción o un objeto social para esta compañía.
